Alentis Therapeutics Doses First ANCA-Associated Vasculitis Rapidly Progressive Glomerulonephritis Patient in Phase 2 Clinical Trial of Lixudebart (ALE.F02)

Contributed by: Business Wire

Logo

Tags

Research

Clinical Trials

Biotechnology

Other Health

Health

Pharmaceutical

Other Science

Science

Oncology

Lixudebart

More Like This

Alentis Receives FDA Orphan Drug Designation for Lixudebart to Treat Idiopathic Pulmonary Fibrosis

Alentis Receives FDA Fast Track Designation for ALE.P02 for the Treatment of CLDN1+ Squamous Solid Tumors

Alentis Therapeutics Raises $181.4 Million in an Oversubscribed Series D Financing to Advance the Clinical Development of Anti-Claudin-1 ADCs in Solid Tumors

Rizwan Velji has joined Alentis Therapeutics as Chief Business Officer (Photo: Alentis Therapeutics)

Alentis Therapeutics Expands Leadership Team with the Appointment of Rizwan Velji as Chief Business Officer

Alberto Toso, Chief Scientific Officer of Alentis Therapeutics (Photo: Alentis Therapeutics)

Alentis Appoints Alberto Toso Chief Scientific Officer

Dr. William Pao has joined Alentis Therapeutics' Board of Directors as an independent member. (Photo: Alentis Therapeutics)

William Pao Joins Alentis Therapeutics as Independent Board Member

PR Newswire associated0

First Patient Dosed in Phase III ProstACT GLOBAL Study of Antibody-based Prostate Cancer Therapy Candidate, TLX591

Alnylam Presents Positive Results from the KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development for the Treatment of Hypertension in Patients at High Cardiovascular Risk